Longeveron (LGVN) Income from Continuing Operations (2020 - 2026)
Longeveron (LGVN) recorded quarterly Income from Continuing Operations of 4775000.0 in Q1 2026, up 11.56% quarter-over-quarter from 5399000.0 in Q4 2025, and up 7.84% on a YoY basis from 4428006.98 in Q1 2025.
Longeveron (LGVN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Longeveron's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 4775000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 7.84% year-over-year to 4775000.0; the TTM figure through Mar 2026 stood at 22881000.0 (down 29.92% YoY), while the FY2025 annual figure was 23287000.0, down 40.95% from the prior year.
- Income from Continuing Operations was 4775000.0 for Q1 2026 at Longeveron, up from 5399000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3394000.0 in Q1 2022 to a low of 7310000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 5003000.0 across 5 years, with a median of 5161000.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations sank 64.59% in 2022, then jumped 38.73% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 6638000.0 in 2022, then advanced by 18.05% to 5440000.0 in 2023, then advanced by 21.31% to 4281000.0 in 2024, then slipped by 26.12% to 5399000.0 in 2025, then grew by 11.56% to 4775000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4775000.0 (Q1 2026), 5399000.0 (Q4 2025), and 7310000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -4.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.78 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Sep 30, 2025 | -7.31 Mn |
| Jun 30, 2025 | -5.40 Mn |
| Mar 31, 2025 | -5.18 Mn |
| Dec 31, 2024 | -4.28 Mn |
| Sep 30, 2024 | -4.65 Mn |
| Jun 30, 2024 | -3.50 Mn |
| Mar 31, 2024 | -4.09 Mn |
| Dec 31, 2023 | -5.44 Mn |
| Sep 30, 2023 | -5.16 Mn |
| Jun 30, 2023 | -5.71 Mn |
| Mar 31, 2023 | -4.72 Mn |
| Dec 31, 2022 | -6.64 Mn |
| Sep 30, 2022 | -5.19 Mn |
| Jun 30, 2022 | -4.22 Mn |
| Mar 31, 2022 | -3.39 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | -4.91 Mn |
| Jun 30, 2021 | -5.06 Mn |